Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants McDavid Stilwell - EVP of Corporate Development; IR and Financial Strategy Denny Lanfear - CEO Jean Viret - CFO Chris Thompson - EVP,Sales Dinesh Purandare - EVP, Commercial Strategy & Operations Conference Call Participants Mohit Bansal - Citi Group Balaji Prasad - Barclays Jason Gerberry - Bank of America Greg Gilbert - Truist Securities Douglas Tsao - H.C. Wainwright Chris Schott - JP ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants David Arrington – Vice President-Investor Relations and Corporate Affairs Denny Lanfear – Chief Executive Officer Jean Viret – Chief Financial Officer Chris Thompson – Executive Vice President-Sales Conference Call Participants Mike Ulz – Baird Ken Cacciatore – Cowan & Company Mohit Bansal – Citigroup Jason Gerberry – Bank of America Chris Schott – JPMorgan Greg Gilbert – Truist Securities ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 | --- | --- | --- | |----------------------------------------------------------------------------------------------|-- ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2020 Results Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants David Arrington - VP of IR & Corporate Affairs Dennis Lanfear - Chairman, President & CEO Jean Viret - CFO Chris Thompson - EVP, Market Access Conference Call Participants Stacy Ku - Cowen and Company Mike Ulz - Baird Mohit Bansal - Citigroup. Douglas Tsao - H.C. Wainwright Chris Schott - JPMorgan Operator Ladies and gentlemen, thank you for standing by. And welcome to the Coherus Bio ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants David Arrington - Vice President of Investor Relations & Corporate Affairs Dennis Lanfear - Chief Executive Officer Jean Viret - Chief Financial Officer Vince Anicett - Chief Operating Officer Thomas Fitzpatrick - Chief Legal Officer Conference Call Participants Mohit Bansal - Citigroup Douglas Tsao - H.C. Wainwright Mike Wolff - Baird Ekaterina Knyazkova - JP Morgan Chase & Co Salim Sy ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2019 Earnings Conference Call November 6, 2019 4:30 PM ET Company Participants David Arrington - Vice President of Investor Relations & Corporate Affairs Denny Lanfear - Chief Executive Officer Jean Viret - Chief Financial Officer Jim Hassard - Senior Vice President of Commercial Thomas Fitzpatrick - Chief Legal Officer Conference Call Participants Chris Schott - JPMorgan Douglas Tsao - H.C. Wainwright Mohit Bansal - Citigroup Ken Cacciatore - Cowen & Company Mike ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3615821 (State or other jurisdiction of inc ...